132546-81-7

Basic information

• Product Name: METHYL 6-MORPHOLINONICOTINATE
• Synonyms: METHYL 6-MORPHOLINONICOTINATE;BUTTPARK 98\12-36;RARECHEM AL BF 1436;Methyl 2-morpholino-5-pyridinecarboxylate;Methyl 6-Morpholin-4-yl-nicotinate;METHYL 6-MORPHOLINONICOTITE
• CAS NO: 132546-81-7
• Molecular Formula: C₁₁H₁₄N₂O₃
• Molecular Weight: 222.24
• Product Categories: blocks;Carboxes;Pyridines
• Mol File: 132546-81-7.mol
• Article Data: 3

Chemical Properties

• Melting Point: 113 °C
• Boiling Point: 383.6 °C at 760 mmHg
• Flash Point: 185.8 °C
• Appearance: /
• Density: 1.208 g/cm³
• Vapor Pressure: 4.36E-06mmHg at 25°C
• Refractive Index: 1.542
• Storage Temp.: 2-8°C
• CAS DataBase Reference: METHYL 6-MORPHOLINONICOTINATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 6-MORPHOLINONICOTINATE(132546-81-7)
• EPA Substance Registry System: METHYL 6-MORPHOLINONICOTINATE(132546-81-7)

Safety Data

• Hazard Codes: Xi
• Statements: R36/37/38:Irritating to eyes, respiratory system and skin.
• Safety Statements: S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.; S37/39:Wear suitable g
• Hazardous Substances Data: 132546-81-7(Hazardous Substances Data)

Usage

General Description

Methyl 6-morpholinonicotinate is a chemical compound with the molecular formula C12H16N2O3. It is also known by its IUPAC name, Methyl 6-(4-morpholinyl)nicotinate. METHYL 6-MORPHOLINONICOTINATE belongs to the family of nicotinic acids and derivatives, with particular structural characteristics including a pyridine ring bonded to a carboxyl group, along with a morpholine ring. Commonly used in scientific research and potentially in the pharmaceutical industry, its exact properties, potential benefits, and side effects can vary based on its use and interactions with other substances. Like many chemicals, it should be handled with care, under controlled laboratory conditions. The substance is not well-documented in general publications, indicating that further studies and exploration into its potential uses and effects are necessary.

InChI:InChI=1/C11H14N2O3/c1-15-11(14)9-2-3-10(12-8-9)13-4-6-16-7-5-13/h2-3,8H,4-7H2,1H3

Upstream product

• 110-91-8 morpholine 
• 73781-91-6 6-Chloronicotinic acid methyl ester 
• 120800-52-4 6-morpholin-4-ylpyridine-3-carboxylic acid 
• 74-88-4 methyl iodide 

Downstream Products

• 251101-37-8 4-(5-methylpyridin-2-yl)morpholine 
• 120800-52-4 6-morpholin-4-ylpyridine-3-carboxylic acid 
• 1232221-78-1 N-(3-methyl-benzylidene)-N'-[7-morpholin-4-yl-2-(6-morpholin-4-yl-pyridin-3-yl)-pyrazolo[1,5-a]pyrimidin-5-yl]-hydrazine 

Relevant articles and documents

PYRAZOLO-PYRIMIDINE COMPOUNDS

The present invention has searched for a variety of compounds which show IL-12/IL-23 production-inhibitory activities and herein provides a pharmaceutical composition and an agent for preventing or treating IL-12/IL-23 excess production-related diseases, which comprise the compound.

FUSED QUINOLINE DERIVATIVE AND USE THEREOF

The present invention aims at provision of a quinoline derivative having a neurokinin 2 (NK2) receptor antagonistic action and relates to a compound represented by the formula (I) wherein Rl is a hydrogen atom and the like; R2 is a hydrogen atom, a hydrocarbon group optionally having substituent(s) and the like; R3 is unsubstituted (i.e., absence), a hydrogen atom and the like; R4 and R5 are the same or different and each is a hydrogen atom, a hydrocarbon group optionally having substituent(s), and the like; R6is (cyclic group optionally having substituent(s)) -carbonyl, and the like; R7, R8,R9 and R10 are the same or different and each is a hydrogen atom, halogen and the like; or R7and R8,R8 and R9,and R9 and R10 may form a ring together with the adjacent carbon atoms; n is an integer of 1 to 5; --- represents unsubstituted (i.e., absence) or a single bond; and --- represents a single bond or a double bond, or a salt thereof, and the like.